Liver cancer treatment: New immunotherapy shows 17% 6-year survival rate

Medical experts are highlighting new advancements in treating advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. A key development is the ‘Stride’ immunotherapy regimen, which consists of a single dose of tremelimumab followed by durvalumab. According to the Himalaya study involving nearly 1,200 patients, this approach achieved a 6-year survival rate of 17.1%, a significant milestone in phase 3 clinical trials for this stage of the disease.

Experts emphasize that treating HCC is uniquely challenging because it often develops in cirrhotic livers, requiring therapies that effectively target the tumor without compromising remaining liver function. The Emerald-3 study is also noted for combining immunotherapy with anti-angiogenic drugs to provide systemic control alongside standard local treatments like chemoembolization.

Additionally, non-invasive technologies such as the Edison Histotripsy System are emerging. This technology uses focused ultrasound to treat liver tumors and has received FDA De Novo authorization. Medical professionals stress the necessity of a multidisciplinary approach, involving oncologists, hepatologists, and surgeons, to balance tumor control with the preservation of vital organ function.